Safety and efficacy of A1H in patients with non-muscle invasive bladder cancer awaiting transurethral surgery: A randomized placebo controlled phase I/II study

by A. Brisuda, J. Háček, J. Horňák, C. Svanborg, M. Babjuk
Published 2020-07-01

Risk tables for predicting progression using the 1973 and 2004/2016 WHO grading classification systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A m...

by R.J. Sylvester, M. Burger, E. Comperat, M. Babjuk, B. Van Rhijn
Published 2020-07-01

PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

by I. A. Korneyev, I. A. Aboyan, B. Ya. Alekseev, O. I. Apolikhin, B. K. Komyakov, V. B. Matveev, M. Colombel, A. Heidenreich, L. Martínez-Piñeiro, M. Babjuk, C. Surcel, P. Yakovlev, R. Colombo, P. Radziszewski, F. Witjes, P. Mulders, R. Schipper, W. Witjes
Published 2014-07-01

PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

by I. A. Korneyev, I. A. Aboyan, B. Ya. Alekseev, O. I. Apolikhin, B. K. Komyakov, V. B. Matveev, M. Colombel, A. Heidenreich, L. Martínez-Piñeiro, M. Babjuk, C. Surcel, P. Yakovlev, R. Colombo, P. Radziszewski, F. Witjes, P. Mulders, R. Schipper, W. Witjes
Published 2014-07-01